Estudo de coorte | O uso de inibidores da 5-alfa-redutase para hiperplasia prostática benigna não está associado com mortalidade aumentada no câncer de próstata.

Comunicado de imprensa: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer – Karolinska Institute

Estudo original: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA Oncology (link para o resumo – $ para o texto completo)

Entrevista com os autores: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA

Comentário: Large study finds no increased risk for prostate cancer death with 5-ARI use – medwire News

Comentário no Twitter

This large population-based cohort study found that men treated with 5α-reductase inhibitors had no increased risk of dying from #prostatecancer, on the contrary indicating a decreased risk with longer treatment duration. https://t.co/y8HlpthNI9 #PCSM #GUCSM

— JAMA Oncology (@JAMAOnc) May 19, 2022